<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer-associated hypercoagulable state: Causes and mechanisms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer-associated hypercoagulable state: Causes and mechanisms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cancer-associated hypercoagulable state: Causes and mechanisms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thita Chiasakul, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Zwicker, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth A Bauer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pathogenesis of thrombosis in malignancy involves an underlying prothrombotic state resulting from cancer-related procoagulant mechanisms, which is further aggravated by clinical risk factors that occur more commonly in cancer patients, such as hospitalization, surgery, catheter insertion, and cancer-directed therapy. </p><p>The causes, mechanisms, and clinical risk factors of cancer-associated thrombosis will be reviewed here. </p><p>Prevention and treatment of hypercoagulable disorders associated with malignancy are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple myeloma</strong> – (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pancreatic cancer</strong> – (See  <a class="medical medical_review" href="/d/html/2505.html" rel="external">"Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other tumors</strong> – (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Primary prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Catheter-related thrombosis</strong> – (See  <a class="medical medical_review" href="/d/html/8195.html" rel="external">"Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deep vein thrombosis and pulmonary embolism</strong> – (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p></p><p class="headingAnchor" id="H1513023536"><span class="h1">ASSOCIATION BETWEEN CANCER AND THROMBOSIS</span><span class="headingEndMark"> — </span>Observations of an association between cancer and an increased risk of thrombosis were made by Armond Trousseau in the mid-1800s. Over 150 years later, it is now well established that thrombosis occurs commonly in cancer patients. Trousseau died of gastric cancer in 1867.</p><p class="bulletIndent1"><span class="glyph">●</span>The cancer-associated hypercoagulable state may present clinically as venous thromboembolism (VTE), arterial thromboembolism, microcirculatory thrombosis, or superficial thrombophlebitis. The risks of venous and arterial thromboembolism are increased several-fold, as discussed separately. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Incidence and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain types of cancers, especially pancreatic, gastric, brain, and ovarian cancers, are associated with a particularly high incidence of thrombosis. Thrombotic complications typically present in close temporal relationship with the diagnosis of cancer but may also precede the diagnosis by months. (See <a class="local">'Cancer-related factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other factors, including cancer therapy, patient age, and comorbidities influence the thrombotic risk in patients with cancer. (See <a class="local">'Patient-related factors'</a> below and <a class="local">'Therapy-related factors'</a> below.)</p><p></p><p class="headingAnchor" id="H737832316"><span class="h1">BIOMARKERS</span><span class="headingEndMark"> — </span>A number of potential biomarkers have been postulated to be useful for identifying patients with cancer at high risk for venous thromboembolism (VTE) and other types of thrombosis, mostly based on mechanistic studies. (See <a class="local">'Molecular mechanisms'</a> below.)</p><p>However, the only biomarkers that have been extensively validated and widely applied to clinical care are the complete blood count (CBC) parameters as elements of the Khorana risk prediction model for VTE in cancer  (<a class="graphic graphic_table graphicRef73002" href="/d/graphic/73002.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>High platelet count – ≥350,000/microL before chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Low hemoglobin – &lt;10 g/dL or use of an erythropoiesis-stimulating agent (ESA)</p><p class="bulletIndent1"><span class="glyph">●</span>High white blood cell (WBC) count – &gt;11,000/microL before chemotherapy</p><p></p><p>D-dimer is a fibrin degradation production released upon cleavage of cross-linked fibrin. Elevations in D-dimer can be indicative of increased thrombin generation due to thrombosis or an underlying prothrombotic state. D-dimer has not been validated as a biomarker for cancer-associated VTE in the same way as the Khorana score, although it appears to correlate with VTE in patients with cancer. In non-cancer populations, D-dimer has high sensitivity and low specificity for VTE. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'D-dimer'</a>.) </p><p>D-dimer values are often higher in cancer cohorts than those without cancer [<a href="#rid1">1</a>]. More extreme elevations (above the 75<sup>th</sup> percentile) have been linked to an increased risk of VTE [<a href="#rid2">2</a>]. D-dimer values can fluctuate over time, and a rising trajectory may improve predictive accuracy [<a href="#rid3">3</a>]. Due to issues with low positive predictive value, unresolved D-dimer cutoffs in cancer, and fluctuating values, D-dimer values are not routinely used in clinical practice to predict thrombosis in individuals with cancer.</p><p>There is keen interest in establishing better and more specific mechanistic biomarkers, such as tissue factor, soluble P-selectin, and neutrophil extracellular traps, but none of these has been validated sufficiently for clinical care. (See <a class="local">'Molecular mechanisms'</a> below.)</p><p class="headingAnchor" id="H3481950009"><span class="h1">MOLECULAR MECHANISMS</span><span class="headingEndMark"> — </span>The hypothesized pathogenesis of venous thrombosis is referred to as Virchow's triad; it consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercoagulability</p><p class="bulletIndent1"><span class="glyph">●</span>Decrease in venous flow (or stasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Vessel wall damage (or endothelial injury)</p><p></p><p>In individuals with cancer, these can be due to the malignancy itself, cancer treatment, and factors not directly related to the cancer.</p><p class="headingAnchor" id="H3465294617"><span class="h2">Procoagulant proteins</span><span class="headingEndMark"> — </span>Cancer cells may express or secrete procoagulant proteins that directly activate the coagulation cascade in the circulation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue factor</strong> – Tissue factor (TF) is a transmembrane protein that plays a critical role in the initiation of coagulation and hemostasis. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Tissue factor'</a>.)</p><p></p><p class="bulletIndent1">In physiologic conditions, TF is expressed on perivascular and epithelial cells. Expressed TF binds to activated factor VII (FVIIa), and the TF-FVIIa complex activates factor IX and factor X, triggering the downstream coagulation cascade. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Activation of factors VII, X, and IX'</a>.)</p><p></p><p class="bulletIndent1">Certain types of tumor cells demonstrate high levels of TF expression. Such cells are capable of releasing TF into the circulation in the form of TF-positive extracellular vesicles, contributing to the development of cancer-associated thrombosis [<a href="#rid4">4,5</a>]. Studies using immunohistochemistry have observed high levels of TF expression predominantly in pancreatic cancer cells [<a href="#rid6">6-8</a>]. Expression has also been seen in other cancer types including cervical, brain, and ovarian cancer [<a href="#rid9">9-11</a>]. </p><p></p><p class="bulletIndent1">TF expression may correlate with tumor histological grade and angiogenesis [<a href="#rid7">7,8,12</a>]. In a retrospective analysis of 41 patients with pancreatic cancer, VTE was more common among patients with high TF-expressing carcinomas than those with low TF-expressing carcinomas (26 versus 5 percent) [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1">Certain oncogenic gene mutations appear to correlate with upregulation of TF expression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>KRAS</em> and <em>TP53 </em>mutation in colorectal cancer [<a href="#rid13">13</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><em>PTEN</em>, <em>TP53,</em> <em>KRAS, </em>and<em> ALK</em> mutation in non-small cell lung cancer [<a href="#rid14">14,15</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>EGFR overexpression and <em>IDH1 </em>wild-type status in glioma [<a href="#rid16">16-18</a>]</p><p></p><p class="bulletIndent1">In addition to intratumoral expression, TF can be carried through the circulation by cancer cell-derived extracellular vesicles [<a href="#rid4">4,19</a>]. These TF-positive extracellular vesicles (TF+ EVs) can be measured in plasma using enzyme-linked immunosorbent assays (ELISA), flow cytometry, or activity-based assays [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1">Although the definitive role of TF+ EVs in clinical VTE remains undetermined in other cancers, several cohort studies have consistently observed an association between plasma TF levels and VTE in pancreatic cancer [<a href="#rid4">4,21-24</a>]. In one study in pancreatic cancer, TF+ EVs were associated with increased mortality but not VTE [<a href="#rid25">25</a>]. The concentration of TF+ EVs can be nearly eliminated after curative pancreatectomy [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Podoplanin </strong>– Podoplanin (PDPN) is a transmembrane protein that activates platelets via binding to platelet C-type lectin-like receptor 2 (CLEC-2) [<a href="#rid26">26,27</a>]. PDPN is expressed on lymphatic endothelial cells and kidney podocytes. It is upregulated in various tumor cells including squamous cell carcinoma, germinal tumors, mesothelioma, and brain tumors [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1">Some studies suggest that PDPN plays a role in cancer-associated thrombosis. In an immunohistochemistry study of primary brain tumors, high PDPN expression was associated with an increased risk of VTE [<a href="#rid29">29</a>]. In a mouse model of ovarian cancer, PDPN-positive EVs were associated with platelet aggregation and VTE [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PAI-1</strong> – Plasminogen activator inhibitor (PAI-1) is the principal inhibitor of plasminogen activators and plasma fibrinolytic activity. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Plasminogen activator inhibitors and alpha-2-antiplasmin'</a>.)</p><p></p><p class="bulletIndent1">PAI-1 levels are elevated in pancreatic cancers [<a href="#rid31">31</a>]. In a study involving 139 pancreatic cancer patients, increased levels of active PAI-1 were independently associated with VTE, with a 40 percent increase in VTE risk per doubling of PAI-1 level [<a href="#rid32">32</a>]. The same study showed that mice bearing pancreatic tumors with PAI-1 overexpression had impaired clot resolution eight days after ligation of the inferior vena cava. These data suggest that elevated PAI-1 and decreased fibrinolysis contribute to the pathogenesis of cancer-associated thrombosis. </p><p></p><p class="bulletIndent1">Conversely, increased expression of the plasminogen receptor annexin A2 on promyelocytic leukemia cells contributed to hyperfibrinolysis and an underlying coagulopathy [<a href="#rid33">33,34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PDI</strong> – Protein disulfide isomerase (PDI) is a thiol isomerase localized in the endoplasmic reticulum that has an essential role in protein folding and disulfide bond formation during protein synthesis. PDI is released from activated platelets or endothelial cells. (See  <a class="medical medical_review" href="/d/html/1330.html" rel="external">"The endothelium: A primer", section on 'Procoagulant properties'</a> and  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Secretion (granule exocytosis)'</a>.)</p><p></p><p class="bulletIndent1">Extracellular PDI may contribute to hypercoagulability in cancer through interactions with different coagulation factors [<a href="#rid35">35,36</a>]. In a study of 65 patients with myeloproliferative neoplasms (MPNs) and 27 healthy controls, elevated plasma PDI levels were detected primarily in JAK2-mutated MPNs and were predictive of VTE and the risk of arterial thromboembolism [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'JAK2 mutations'</a> and  <a class="medical medical_review" href="/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera", section on 'Thrombosis and hemorrhage'</a>.)</p><p></p><p class="bulletIndent1">Quercetin flavonoids, found in fruits and vegetables, have been identified as PDI inhibitors. In a phase 2 trial in patients with advanced colorectal, pancreatic, or lung cancer, inhibition of PDI with isoquercetin significantly reduced the levels of plasma D-dimer, soluble P-selectin, and platelet-dependent thrombin generation [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/138700.html" rel="external">"Investigational anticoagulants", section on 'Protein disulfide isomerase inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H2235582604"><span class="h2">Endothelial cells, WBCs, and platelets</span><span class="headingEndMark"> — </span>Tumor cells may express proteins that interact with non-cancer cells and promote thrombosis. Elevated white blood cell (WBC) count and platelet count are two of the biomarkers validated for clinical use as part of the Khorana score. (See <a class="local">'Biomarkers'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endothelial cells</strong> – Inflammatory cytokines released from cancer cells, such as tumor necrosis factor (TNF-) alpha, interleukin (IL-) 1beta, IL-6, IL-8, and vascular endothelial growth factor (VEGF), can induce a procoagulant phenotype in endothelial cells. The phenotype includes expression of TF, release of von Willebrand factor (VWF), and release of plasminogen activator inhibitor 1 (PAI-1) [<a href="#rid39">39</a>]. (See <a class="local">'Procoagulant proteins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WBCs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukocytosis</strong> – Elevated WBC counts are frequently observed in patients with cancer and are associated with VTE in this population [<a href="#rid40">40-42</a>]. In the derivation cohort of the Khorana score, pre-chemotherapy WBC count &gt;11,000/microL was associated with doubling in the risk of VTE (odds ratio [OR] 2.2, 95% CI 1.2-4) [<a href="#rid43">43</a>]. Analysis of a cohort from the Vienna Cancer and Thrombosis Study (CATS) showed a 7 percent increase in the risk of VTE per 1000/microL increase in the WBC count [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutrophil extracellular traps (NETs)</strong> – NETs are extracellular decondensed chromatin fibers decorated with granular proteins and histones. NETs are released from activated or dying neutrophils, mediated by the enzyme peptidylarginine deiminase 4 (PADI4) [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent2">NET formation (NETosis) promotes thrombosis by providing a scaffold for platelet and fibrin deposition, activating factor XIIa, binding to VWF, and inactivating tissue factor pathway inhibitor (TFPI) [<a href="#rid44">44,45</a>]. </p><p></p><p class="bulletIndent2">Biomarkers associated with NETs include citrullinated histone H3 (H3Cit), myeloperoxidase, nucleosomes, neutrophil elastase, and cell-free DNA (cfDNA) [<a href="#rid46">46</a>]. In one cohort, elevated levels of H3Cit were associated with an increased risk of VTE in cancer patients for up to two years, specifically in individuals with cancer of the pancreas, lung, or breast [<a href="#rid47">47</a>]. Elevated levels of cfDNA and nucleosomes were also associated with increased risk of VTE in the first three to six months following the diagnosis of cancer or disease progression. The magnitude of risk was comparable with previously identified biomarkers for VTE in patients with cancer, such as D-dimer, soluble P-selectin, and factor VIII levels [<a href="#rid47">47</a>]. Questions have been raised regarding the sensitivity and specificity of different NET assays [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monocytes</strong> – Activated monocytes can express TF on their surface and can be a major source of procoagulant TF in the circulation. (See <a class="local">'Procoagulant proteins'</a> above.)</p><p></p><p class="bulletIndent2">Increased monocyte count has been shown as a risk factor for VTE in cancer patients [<a href="#rid49">49,50</a>]. In one study in ambulatory cancer patients, an absolute monocyte count &gt;1200/microL was associated with an increased risk of VTE [<a href="#rid49">49</a>]. In another study of hospitalized cancer patients, a monocyte count &gt;500/microL was associated with a 5-fold increased risk of VTE [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelets</strong> – Thrombocytosis, identified prior to or at the time of cancer diagnosis, is associated with VTE in cancer patients [<a href="#rid40">40,51,52</a>]. Different cutoffs for defining thrombocytosis were used in these studies (platelet count of &gt;443,000/microL, ≥350,000/microL, or ≥295,000/microL); the Khorana score uses ≥350,000/microL before chemotherapy. (See <a class="local">'Biomarkers'</a> above.)</p><p></p><p class="bulletIndent1">In another study, an inverse relationship was found in patients with high-grade glioma, whereby low platelet count was associated with an increased risk of VTE (hazard ratio 0.73 for each 50,000/microL increase in platelet count, 95% CI 0.53-0.95) [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">Activated platelets express P-selectin, and increased levels of circulating soluble P-selectin have been shown to be associated with VTE in cancer populations [<a href="#rid53">53-55</a>]. </p><p></p><p class="bulletIndent1">In a general cancer population study, other biomarkers of platelet activation such as soluble CD40 ligand, thrombospondin-1, and platelet factor-4 (PF4) were not associated with increased risk of VTE [<a href="#rid55">55</a>]. However, in a subgroup with pancreatic cancer, high PF4 levels were associated with a 2.7-fold increased risk of VTE. </p><p></p><p class="headingAnchor" id="H525219148"><span class="h1">CONTRIBUTING FACTORS</span><span class="headingEndMark"> — </span>The risks of thrombosis in individual cancer patients are influenced by numerous factors. Some are unique to cancer, and others may overlap with non-cancer populations  (<a class="graphic graphic_table graphicRef139866" href="/d/graphic/139866.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3876868270"><span class="h2">Cancer-related factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type</strong> – Cancer type is one of the most important risk factors for cancer-associated thrombosis. The highest risks of VTE are observed in pancreatic, stomach, brain, colorectal, lung, and ovarian cancers [<a href="#rid56">56-58</a>]. </p><p></p><p class="bulletIndent1">In the Khorana score, stomach and pancreatic cancers are considered very high risk (odds ratio [OR] 4.3, 95% CI 1.2-15.6) and are each assigned two points [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'VTE risk assessment/Khorana score'</a>.)</p><p></p><p class="bulletIndent1">Breast and prostate cancers, which are more common, have relatively lower risks of VTE [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage</strong> – VTE risk increases with more advanced cancer stage. In one study, regional disease had a 3.7-fold higher risk of VTE than local disease [<a href="#rid59">59</a>]. Metastatic disease at the time of diagnosis is one of the strongest risk factors for VTE and is associated with 1.4- to 21.5-fold higher risk of VTE depending on cancer type [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grade</strong> – Histological grade of a tumor influences the risk of VTE. In one study, patients with high-grade tumors had twice the VTE risk of those with low-grade tumors [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing relative to diagnosis </strong>– Risks of cancer-associated thrombosis are highest during the period immediately following the diagnosis of cancer, probably due to the active disease status, the intensity of treatments received, and associated hospitalization and procedures [<a href="#rid57">57,62,63</a>]. The risk of VTE following diagnosis gradually decreases over time [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>VTE</strong> – One study found that the incidence of VTE started to increase over that expected four months prior to the diagnosis of certain cancers (acute myeloid leukemia, non-Hodgkin lymphoma, and pancreatic, ovarian, stomach, renal cell, and lung cancer) [<a href="#rid64">64</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Arterial thromboembolism</strong> – One study found that the risk of arterial thrombosis progressively increased starting 150 days before the diagnosis of cancer and peaked during the 30 days immediately before diagnosis [<a href="#rid63">63</a>]. At six months after diagnosis, the risk of arterial thromboembolism doubled compared with controls; the excess risk evens out with controls at approximately one year after diagnosis [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene variants</strong> – In some cancer types, specific pathogenic variants in certain genes influence the risks of VTE. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased risks of VTE are associated with <em>JAK2</em> V617F mutation in myeloproliferative neoplasms (MPNs) [<a href="#rid65">65,66</a>], <em>ALK</em> mutation or <em>ROS1</em> rearrangement in lung cancer [<a href="#rid67">67-69</a>], and wild-type <em>IDH1</em> in brain tumors [<a href="#rid70">70</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a genomic analysis of solid tumors, tumor-specific mutations <em>in KRAS, STK11, KEAP1, CTNNB1, CDKN2B, </em>a<em>nd MET </em>were associated with increased risks of VTE, whereas mutations in <em>SETD2</em> were associated with a decreased risk of VTE [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H3871243847"><span class="h2">Patient-related factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – As in the general population, the risks of VTE generally increase with age in cancer patients, although the effect is quite modest (for age ≥65 years, the odds ratio in one study was 1.08, 95% CI 1.05-1.1) or is even not captured in some studies [<a href="#rid57">57,60,72</a>]. In the more highly thrombotic cancer types (pancreas, stomach) as well as lung cancer and mesothelioma, the effect is reversed, so that younger age is associated with higher risks of VTE [<a href="#rid57">57,60</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary thrombophilia</strong> – Factor V Leiden and other prothrombotic genetic variants, including prothrombin G20210A and variants in the <em>ABO</em>, <em>FGG</em>, and <em>F11</em> genes have been shown to confer additional risk of VTE in patients with cancer [<a href="#rid73">73-75</a>]. </p><p></p><p class="bulletIndent1">TiC-Onco is a risk assessment model that incorporates a genetic risk score using four genetic variants with other clinical variables [<a href="#rid76">76</a>]. The score has comparable performance to the Khorana score, although further validation is needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other VTE risk factors </strong>– Patients with cancer may also have other comorbidities or conditions that are known to increase VTE risk, such as prior history of VTE, high body mass index (BMI), family history of VTE, or acute illness [<a href="#rid77">77</a>]. Of these, prior history of VTE is the most important risk factor, associated with an eight-fold increased risk of VTE [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DIC</strong> – We do not consider disseminated intravascular coagulation (DIC), especially when it is acute, to be a mechanism of VTE similar to those described above. </p><p></p><p class="bulletIndent1">However, chronic DIC in patients with cancer carries a high risk of thrombosis. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Chronic DIC'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – Relatively high incidences of VTE have been observed in hospitalized patients with coronavirus disease 2019 (COVID-19), and patients with cancer may be at higher risk of developing VTE during COVID-19 infection compared with non-cancer patients [<a href="#rid78">78-80</a>]. Among cancer patients hospitalized with COVID-19, VTE risk was increased in those with recent cancer therapy, VTE history, and/or direct intensive care unit (ICU) admission [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1">The CoVID-TE risk assessment model was proposed as a risk-stratification tool for VTE in cancer populations [<a href="#rid81">81</a>]. The model stratifies hospitalized patients with cancer and COVID-19 into low-risk and high-risk cohorts, with a corresponding VTE risk of 4.1 versus 11.3 percent. </p><p></p><p class="headingAnchor" id="H2544858919"><span class="h2">Therapy-related factors</span><span class="headingEndMark"> — </span>In a 2021 population-based study, receiving cancer treatment during the first four months after a cancer diagnosis was identified as a risk factor for VTE [<a href="#rid56">56</a>]. Cancer treatments that increased VTE risk included targeted therapy (hazard ratio [HR] 3.85, 95% CI 3.43-4.32), chemotherapy (HR 3.35, 95% CI 3.06-3.66), surgery (HR 2.20, 95% CI 2.02-2.39), and radiotherapy (HR 2.16, 95% CI 1.94-2.39) [<a href="#rid56">56</a>]. Risk was not significantly increased with hormonal therapy in this study. </p><p class="headingAnchor" id="H2836018824"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapeutic drugs have been identified as an important independent risk factor for VTE in cancer patients, increasing the risk of VTE three-fold compared with no treatment and 24-fold compared with matched controls without cancer [<a href="#rid56">56</a>]. Analysis of the use of chemotherapy showed that the proportion of cancer patients receiving chemotherapy during the first four months after cancer diagnosis has doubled from 17 percent in 1997 to 33 percent in 2017 [<a href="#rid56">56</a>]. </p><p>The thrombotic risk varies with different chemotherapeutic agents. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong> – Cisplatin-based chemotherapy has been the most notable in terms of its thrombotic risk. A systematic review and meta-analysis of 8216 patients from 38 randomized controlled trials showed a significantly increased risk of VTE in patients treated with cisplatin-based chemotherapy compared with non-cisplatin-based regimens (relative risk [RR] 1.67, 95% CI 1.25-2.23) [<a href="#rid82">82</a>]. Regimens in the control arm also included oxaliplatin- and carboplatin-based therapy. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> does not appear to confer this degree of thromboembolic risk; in a randomized trial, thromboembolism occurred in 13 to 17 percent of individuals randomly assigned to receive a cisplatin-containing regimen versus 8 percent of individuals assigned to receive an oxaliplatin-containing regimen [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1">The risk of arterial thromboembolism was not found to be increased with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asparaginase</strong> – Asparaginase depletes the amino acid asparagine, required for synthesis of asparagine-containing proteins including antithrombin. </p><p></p><p class="bulletIndent1">Prevention and management of VTE in patients receiving asparaginase are discussed separately. (See  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'Patients receiving asparaginase'</a>.)</p><p></p><p class="headingAnchor" id="H2530058595"><span class="h3">Hormonal therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tamoxifen</strong> – <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> is a selective estrogen receptor modulator; it is associated with an increased risk of VTE, especially in the first years of treatment [<a href="#rid85">85-89</a>]. A prospective cohort study reported that tamoxifen initiation was associated with increased thrombin generation and increased protein C resistance from baseline as evidenced by thrombin generation assay [<a href="#rid90">90</a>]. Fibrinogen, antithrombin, protein C, and TFPI were also decreased post-treatment, effects not found with aromatase inhibitors.</p><p></p><p class="bulletIndent1">Data from prevention trials in individuals without cancer also indicate that <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> increases VTE risk. Examples include the NSABP P-1 Breast Cancer Prevention Trial (BCPT), which included over 13,000 patients randomly assigned to tamoxifen or placebo and showed an increased risk for VTE (risk ratio for pulmonary embolism 3.0, 95% CI 1.1-11.2, and for deep vein thrombosis 1.6, 95% CI 0.9-2.9) [<a href="#rid91">91</a>]. The International Breast Cancer Intervention Study (IBIS-1), which randomly assigned over 7000 patients to tamoxifen or placebo, found an increased risk of VTE with tamoxifen (OR 2.1, 95% CI 1.1-4.1) [<a href="#rid92">92</a>]. Risk was further increased in patients who had surgery, immobilization, or fracture in the month prior to the event, and it persisted during five years of active treatment but not following discontinuation [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Available data on risk of arterial thrombosis are conflicting, and a potential increased risk of stroke may be balanced by a potential decreased risk of myocardial infarction:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), which compared 21,457 women randomly assigned to receive <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> or control (identical chemotherapy without tamoxifen, placebo), there was a trend toward increased stroke-related mortality that did not reach the level of statistical significance (3 extra deaths per 1000 patients during the first 15 years, none of which occurred during treatment) [<a href="#rid94">94</a>]. However, there was a reciprocal trend toward decreased cardiac mortality (3 fewer deaths per 1000 patients during the first 15 years). Thus, the overall vascular mortality was similar with tamoxifen versus no tamoxifen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a case-control study of 11,045 women with breast cancer, the risk of stroke was not increased by the use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> (OR 1.0, 95% CI 0.6-1.6) [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of randomized trials of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> use for breast cancer (primary or secondary prevention) that included 39,601 patients, the frequency of ischemic stroke was greater in those who received tamoxifen than controls (0.71 versus 0.39 percent; mean duration of follow-up 4.9 years) [<a href="#rid96">96</a>]. It was concluded that tamoxifen was associated with an increased stroke risk, although the absolute risk was small. This study did not evaluate myocardial ischemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Raloxifene</strong> – <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">Raloxifene</a> is a selective estrogen receptor modulator used for prevention of osteoporosis and breast cancer. In a meta-analysis that included nearly 25,000 post-menopausal individuals without cancer, raloxifene was associated with an increased risk for VTE (OR 1.62, 95% CI 1.25-2.09) [<a href="#rid97">97</a>]. A US Preventive Services Task Force analysis comparing <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and raloxifene for breast cancer prevention found that the odds ratio for VTE was lower for raloxifene (1.56, versus 1.9 for tamoxifen) [<a href="#rid98">98</a>].</p><p></p><p>Aromatase inhibitors (<a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a>, <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a>, and <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>) do not appear to increase the risk of VTE [<a href="#rid99">99</a>]. </p><p class="headingAnchor" id="H3249131428"><span class="h3">Targeted and immunological therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclin-dependent kinase inhibitors</strong> – Inhibitors of cyclin-dependent kinase 4/6, such as <a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">palbociclib</a>, <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a>, and <a class="drug drug_general" data-topicid="112288" href="/d/drug information/112288.html" rel="external">ribociclib</a>, are associated with increased risk of thromboembolic complications. The overall one-year incidence of venous and arterial thrombosis was 10.4 percent in patients receiving these drugs [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiangiogenic agents</strong> – Increased thrombotic risk has been observed with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>. A systematic review and meta-analysis of 7956 patients from 15 randomized clinical trials showed an 11.9 percent incidence of VTE among patients who received bevacizumab, with an RR of 1.33 (95% CI 1.13-1.56) compared with controls [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Arterial and venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulatory drugs (IMiDs) and glucocorticoids </strong>– <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a> and <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> are associated with increased risk of VTE when used in combination with chemotherapy or glucocorticoids [<a href="#rid102">102-104</a>]. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism", section on 'VTE incidence and risk factors'</a>.)</p><p></p><p class="bulletIndent1">High-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> appears to particularly increase VTE risk. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism", section on 'Immunomodulatory drugs'</a>.)</p><p></p><p class="bulletIndent1">Glucocorticoids do not appear to be a major risk factor for VTE in other settings besides combination with an IMiD in patients with multiple myeloma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy and CAR-T cells</strong> – The off-target effects of T-cell activation by immune checkpoint inhibitors such as PD-L1 or CTLA4 inhibitors can cause immune-mediated vasculitis and monocyte activation, leading to heightened thrombotic risk [<a href="#rid105">105</a>]. Incidences of VTE in retrospective analyses of cancer patients who received immunotherapy ranged from 4 to 24 percent [<a href="#rid106">106</a>]. Compared with cancer patients who did not receive treatment, immune checkpoint inhibitors significantly increased the risk of VTE (adjusted HR 2.78, 95% CI 1.61-4.80) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Cardiovascular toxicity'</a>.)</p><p></p><p class="bulletIndent1">Chimeric antigen receptor T cell (CAR-T) therapy may increase VTE risk. In one study, new VTE occurred in 6.7 to 11 percent within the first three months after CAR-T cell infusion [<a href="#rid107">107,108</a>]. The magnitude of increased risk compared with controls is challenging to determine. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Cancer therapy'</a>.)</p><p></p><p class="headingAnchor" id="H3692473185"><span class="h3">Erythropoiesis stimulating agents</span><span class="headingEndMark"> — </span>Erythropoiesis stimulating agents (ESAs) are sometimes used for anemia associated with cancer. In a Cochrane systematic review of 57 trials, the risk ratio for thromboembolic complications was increased in patients receiving ESAs compared with controls (RR 1.52, 95% CI 1.34-1.74) [<a href="#rid109">109</a>]. Use of ESAs is assigned a score of 1 in the Khorana score for the prediction of cancer-associated thrombosis [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'VTE risk assessment/Khorana score'</a> and  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Issues related to thromboembolic risk'</a>.)</p><p class="headingAnchor" id="H3361530236"><span class="h3">Cancer surgery and hospitalization</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Inpatients (VTE prophylaxis)'</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H1130671617"><span class="h3">Indwelling catheters or ports</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/8195.html" rel="external">"Catheter-related upper extremity venous thrombosis in adults", section on 'Epidemiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/8195.html" rel="external">"Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H679468032"><span class="h1">DRUG-INDUCED THROMBOTIC MICROANGIOPATHY</span><span class="headingEndMark"> — </span>Several cancer drugs can cause a drug-induced thrombotic microangiopathy (DITMA), as summarized in the table  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 3</a>). </p><p>The mechanism may be immune or non-immune. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Drugs (immune mechanism)'</a> and  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Drugs (non-immune mechanism)'</a>.)</p><p class="headingAnchor" id="H1176690732"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association of cancer with thrombosis</strong> – It is well established that thrombosis occurs commonly in cancer patients, including venous thromboembolism (VTE) and arterial thrombosis. The magnitude of risk and prevention strategies are discussed separately. (See <a class="local">'Association between cancer and thrombosis'</a> above and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Incidence and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomarkers</strong> – The only biomarkers that have been extensively validated and widely applied to clinical care are the complete blood count (CBC) parameters as elements of the Khorana risk prediction model for VTE in cancer; these include platelet count ≥350,000/microL, hemoglobin &lt;10 g/dL (or use of an erythropoiesis-stimulating agent [ESA]), and white blood cell (WBC) count &gt;11,000/microL  (<a class="graphic graphic_table graphicRef73002" href="/d/graphic/73002.html" rel="external">table 1</a>). (See <a class="local">'Biomarkers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms </strong>– Cancer cells may express or secrete procoagulant proteins that directly activate the coagulation cascade in the circulation, especially tissue factor (TF) on the cells or on circulating microparticles. Elevations in other proteins (D-dimer, podoplanin, plasminogen activator inhibitor 1 [PAI-1], protein disulfide isomerase [PDI]) and cells (platelets, WBCs, neutrophil extracellular traps [NETs]), may be surrogates for increased VTE risk or may contribute to the increased risk. We consider disseminated intravascular coagulation (DIC) to be a separate mechanism. (See <a class="local">'Molecular mechanisms'</a> above and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Chronic DIC'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contributing factors</strong> – Factors that contribute to the hypercoagulable state in cancer include  (<a class="graphic graphic_table graphicRef139866" href="/d/graphic/139866.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer type, stage, and timing</strong> – Cancer type is one of the most important risk factors for cancer-associated thrombosis. The highest risks of VTE are observed in pancreatic, stomach, brain, colorectal, lung, and ovarian cancers. Cancer stage, grade, and timing relative to diagnosis also affect VTE risk. Risk is highest from three to four months before diagnosis and may return to baseline at one year after diagnosis. (See <a class="local">'Cancer-related factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient age and comorbidities</strong> – VTE risk increases with patient age and other risk factors not directly related to cancer (high body mass index [BMI], inherited thrombophilia, prior history of VTE, COVID-19). (See <a class="local">'Patient-related factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy</strong> – Chemotherapeutic agents with the highest risk of VTE include <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and asparaginase. Other therapies with increased risk of VTE include <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>, cyclin-dependent kinase inhibitors, antiangiogenic agents, immunomodulatory drugs (<a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> and analogs), immunotherapies, and erythropoiesis stimulating agents. Surgery, hospitalization, and indwelling catheters and ports also increase VTE risk. (See <a class="local">'Therapy-related factors'</a> above.)</p><p></p><p class="bulletIndent2">Risk reduction in patients receiving these is discussed separately. (See  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'Patients receiving asparaginase'</a> and  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a> and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Primary prevention'</a>.)</p><p></p><p class="headingAnchor" id="H2562123088"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lawrence LK Leung, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yu J, Li D, Lei D, et al. Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study. PLoS One 2016; 11:e0165390.</a></li><li><a class="nounderline abstract_t">Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124.</a></li><li><a class="nounderline abstract_t">Posch F, Riedl J, Reitter EM, et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study. J Thromb Haemost 2020; 18:1348.</a></li><li><a class="nounderline abstract_t">Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15:6830.</a></li><li><a class="nounderline abstract_t">Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130:1499.</a></li><li><a class="nounderline abstract_t">Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70:1194.</a></li><li><a class="nounderline abstract_t">Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82:1101.</a></li><li><a class="nounderline abstract_t">Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13:2870.</a></li><li><a class="nounderline abstract_t">Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96:290.</a></li><li><a class="nounderline abstract_t">Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013; 131:162.</a></li><li><a class="nounderline abstract_t">Zhao X, Cheng C, Gou J, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med 2018; 16:4075.</a></li><li><a class="nounderline abstract_t">Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77:1877.</a></li><li><a class="nounderline abstract_t">Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734.</a></li><li><a class="nounderline abstract_t">Regina S, Rollin J, Bléchet C, et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008; 3:689.</a></li><li><a class="nounderline abstract_t">Regina S, Valentin JB, Lachot S, et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009; 55:1834.</a></li><li><a class="nounderline abstract_t">Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010; 116:815.</a></li><li><a class="nounderline abstract_t">Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69:2540.</a></li><li><a class="nounderline abstract_t">Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 2016; 132:917.</a></li><li><a class="nounderline abstract_t">Hisada Y, Ay C, Auriemma AC, et al. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost 2017; 15:2208.</a></li><li><a class="nounderline abstract_t">Hisada Y, Mackman N. Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6:1983.</a></li><li><a class="nounderline abstract_t">Kobayashi S, Koizume S, Takahashi T, et al. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci 2021; 112:4679.</a></li><li><a class="nounderline abstract_t">Bharthuar A, Khorana AA, Hutson A, et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132:180.</a></li><li><a class="nounderline abstract_t">Kasthuri RS, Hisada Y, Ilich A, et al. Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. Res Pract Thromb Haemost 2020; 4:636.</a></li><li><a class="nounderline abstract_t">Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10:1363.</a></li><li><a class="nounderline abstract_t">Suzuki-Inoue K, Fuller GL, García A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107:542.</a></li><li><a class="nounderline abstract_t">Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007; 282:25993.</a></li><li><a class="nounderline abstract_t">Suzuki-Inoue K, Osada M, Ozaki Y. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. J Thromb Haemost 2017; 15:219.</a></li><li><a class="nounderline abstract_t">Riedl J, Preusser M, Nazari PM, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017; 129:1831.</a></li><li><a class="nounderline abstract_t">Sasano T, Gonzalez-Delgado R, Muñoz NM, et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost 2022; 20:104.</a></li><li><a class="nounderline abstract_t">Andrén-Sandberg A, Lecander I, Martinsson G, Astedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992; 69:2884.</a></li><li><a class="nounderline abstract_t">Hisada Y, Garratt KB, Maqsood A, et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Adv 2021; 5:487.</a></li><li><a class="nounderline abstract_t">Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.</a></li><li><a class="nounderline abstract_t">David S, Mathews V. Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thromb Res 2018; 164 Suppl 1:S82.</a></li><li><a class="nounderline abstract_t">Stopa JD, Zwicker JI. The intersection of protein disulfide isomerase and cancer associated thrombosis. Thromb Res 2018; 164 Suppl 1:S130.</a></li><li><a class="nounderline abstract_t">Stopa JD, Neuberg D, Puligandla M, et al. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight 2017; 2:e89373.</a></li><li><a class="nounderline abstract_t">Sharda AV, Bogue T, Barr A, et al. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms. Clin Cancer Res 2021; 27:5708.</a></li><li><a class="nounderline abstract_t">Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel) 2018; 10.</a></li><li><a class="nounderline abstract_t">Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104:2822.</a></li><li><a class="nounderline abstract_t">Blix K, Jensvoll H, Brækkan SK, Hansen JB. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study. PLoS One 2013; 8:e73447.</a></li><li><a class="nounderline abstract_t">Pabinger I, Posch F. Flamethrowers: blood cells and cancer thrombosis risk. Hematology Am Soc Hematol Educ Program 2014; 2014:410.</a></li><li><a class="nounderline abstract_t">Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902.</a></li><li><a class="nounderline abstract_t">Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018; 18:134.</a></li><li><a class="nounderline abstract_t">Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123:2768.</a></li><li><a class="nounderline abstract_t">Thålin C, Hisada Y, Lundström S, et al. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. Arterioscler Thromb Vasc Biol 2019; 39:1724.</a></li><li><a class="nounderline abstract_t">Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost 2018; 16:508.</a></li><li><a class="nounderline abstract_t">Thålin C, Aguilera K, Hall NW, et al. Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma. J Thromb Haemost 2020; 18:2732.</a></li><li><a class="nounderline abstract_t">Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126:113.</a></li><li><a class="nounderline abstract_t">Rojnuckarin P, Uaprasert N, Sriuranpong V. Monocyte count associated with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors. Thromb Res 2012; 130:e279.</a></li><li><a class="nounderline abstract_t">Jensvoll H, Blix K, Brækkan SK, Hansen JB. Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study. PLoS One 2014; 9:e92011.</a></li><li><a class="nounderline abstract_t">Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8:114.</a></li><li><a class="nounderline abstract_t">Thaler J, Ay C, Kaider A, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol 2014; 16:1645.</a></li><li><a class="nounderline abstract_t">Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703.</a></li><li><a class="nounderline abstract_t">Riedl J, Hell L, Kaider A, et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets 2016; 27:80.</a></li><li><a class="nounderline abstract_t">Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137:1959.</a></li><li><a class="nounderline abstract_t">Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49:1404.</a></li><li><a class="nounderline abstract_t">Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res 2020; 191 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98:1309.</a></li><li><a class="nounderline abstract_t">Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458.</a></li><li><a class="nounderline abstract_t">Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30:3870.</a></li><li><a class="nounderline abstract_t">Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol 2017; 70:926.</a></li><li><a class="nounderline abstract_t">Navi BB, Reiner AS, Kamel H, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019; 133:781.</a></li><li><a class="nounderline abstract_t">White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165:1782.</a></li><li><a class="nounderline abstract_t">Pérez Encinas MM, Sobas M, Gómez-Casares MT, et al. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. Eur J Haematol 2021; 106:371.</a></li><li><a class="nounderline abstract_t">Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117:5857.</a></li><li><a class="nounderline abstract_t">Roopkumar J, Poudel SK, Gervaso L, et al. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. J Thromb Haemost 2021; 19:822.</a></li><li><a class="nounderline abstract_t">Dou F, Zhang Y, Yi J, et al. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study. Thromb Res 2020; 186:36.</a></li><li><a class="nounderline abstract_t">Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer 2020; 21:15.</a></li><li><a class="nounderline abstract_t">Mir Seyed Nazari P, Riedl J, Preusser M, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost 2018; 16:1121.</a></li><li><a class="nounderline abstract_t">Dunbar A, Bolton KL, Devlin SM, et al. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood 2021; 137:2103.</a></li><li><a class="nounderline abstract_t">Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339.</a></li><li><a class="nounderline abstract_t">Gran OV, Brækkan SK, Hansen JB. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res 2018; 164 Suppl 1:S12.</a></li><li><a class="nounderline abstract_t">Pabinger I, Ay C, Dunkler D, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost 2015; 13:17.</a></li><li><a class="nounderline abstract_t">Skille H, Paulsen B, Hveem K, et al. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost 2020; 18:2861.</a></li><li><a class="nounderline abstract_t">Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 2018; 118:1056.</a></li><li><a class="nounderline abstract_t">Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17:297.</a></li><li><a class="nounderline abstract_t">Nopp S, Moik F, Jilma B, et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4:1178.</a></li><li><a class="nounderline abstract_t">Alpert N, Rapp JL, Marcellino B, et al. Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study. JNCI Cancer Spectr 2021; 5:Pkaa085.</a></li><li><a class="nounderline abstract_t">Patell R, Bogue T, Bindal P, et al. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost 2020; 18:2349.</a></li><li><a class="nounderline abstract_t">Li A, Kuderer NM, Hsu CY, et al. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost 2021; 19:2522.</a></li><li><a class="nounderline abstract_t">Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012; 30:4416.</a></li><li><a class="nounderline abstract_t">Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36.</a></li><li><a class="nounderline abstract_t">Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:1837.</a></li><li><a class="nounderline abstract_t">Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286.</a></li><li><a class="nounderline abstract_t">Hernandez RK, Sørensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115:4442.</a></li><li><a class="nounderline abstract_t">Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111:650.</a></li><li><a class="nounderline abstract_t">Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev 2012; 38:318.</a></li><li><a class="nounderline abstract_t">Lin HF, Liao KF, Chang CM, et al. Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: A case-control study. Medicine (Baltimore) 2018; 97:e12842.</a></li><li><a class="nounderline abstract_t">Blondon M, Bodmer A, Thouvenin L, et al. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Adv 2022; 6:2884.</a></li><li><a class="nounderline abstract_t">Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.</a></li><li><a class="nounderline abstract_t">Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.</a></li><li><a class="nounderline abstract_t">Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.</a></li><li><a class="nounderline abstract_t">Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96:1528.</a></li><li><a class="nounderline abstract_t">Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004; 63:1230.</a></li><li><a class="nounderline abstract_t">Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008; 99:338.</a></li><li><a class="nounderline abstract_t">Nelson HD, Fu R, Zakher B, et al. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2019; 322:868.</a></li><li><a class="nounderline abstract_t">Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.</a></li><li><a class="nounderline abstract_t">West MT, Smith CE, Kaempf A, et al. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol 2021; 106:634.</a></li><li><a class="nounderline abstract_t">Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277.</a></li><li><a class="nounderline abstract_t">Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614.</a></li><li><a class="nounderline abstract_t">Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9:653.</a></li><li><a class="nounderline abstract_t">Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer 2020; 126:1640.</a></li><li><a class="nounderline abstract_t">Goel A, Khorana A, Kartika T, et al. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. Eur J Haematol 2022; 108:271.</a></li><li><a class="nounderline abstract_t">Roopkumar J, Swaidani S, Kim AS, et al. Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med 2021; 2:423.</a></li><li><a class="nounderline abstract_t">Hashmi H, Mirza AS, Darwin A, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv 2020; 4:4086.</a></li><li><a class="nounderline abstract_t">Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv 2021; 5:4465.</a></li><li><a class="nounderline abstract_t">Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12:CD003407.</a></li></ol></div><div id="topicVersionRevision">Topic 1353 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27835633" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636003" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073229" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861441" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807983" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer-associated pathways and biomarkers of venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381270" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Immunohistochemical identification of tissue factor in solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7648165" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tissue factor expression correlates with histological grade in human pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17504985" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211468" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084660" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30402151" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Expression of tissue factor in human cervical carcinoma tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8646688" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Expression of tissue factor correlates with grade of malignancy in human glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494427" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594312" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661141" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20462964" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19276385" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664011" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mutant IDH1 and thrombosis in gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28834179" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34359742" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18795992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382298" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23856554" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548563" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520016" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174766" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17616532" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27960039" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073783" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34608736" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591681" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33496742" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10099141" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Annexin II and bleeding in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703489" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mechanisms and management of coagulopathy in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703471" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The intersection of protein disulfide isomerase and cancer associated thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097231" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34400417" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30652973" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30314362" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284987" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24023876" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsøstudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25696887" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Flamethrowers: blood cells and cancer thrombosis risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216292" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development and validation of a predictive model for chemotherapy-associated thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990587" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neutrophil extracellular traps in immunity and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366358" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Thrombosis: tangled up in NETs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31315434" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29325226" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20684071" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079295" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Monocyte count associated with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24642868" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the TromsøStudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889150" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24987133" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539899" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970326" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association of platelet activation markers with cancer-associated venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33171494" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Venous thromboembolism in cancer patients: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146958" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736775" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23585523" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505267" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Incidence of venous thromboembolism and its effect on survival among patients with common cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818202" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Risk of Arterial Thromboembolism in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30578253" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Arterial thromboembolic events preceding the diagnosis of cancer in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087828" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275803" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490340" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33314597" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31864154" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31607443" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29676036" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33270827" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918266" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703469" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prothrombotic genotypes and risk of venous thromboembolism in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381723" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32671915" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588512" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282243" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk factors for venous thromboembolic events in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33043231" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33437923" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692862" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34260813" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150697" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172173" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Capecitabine and oxaliplatin for advanced esophagogastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23093559" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988575" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569248" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699284" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21775065" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30572423" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35086148" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747868" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243915" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312304" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802721" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494603" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Stroke risk and tamoxifen therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477543" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278183" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479143" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743022" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527479" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017914" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520815" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255254" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31913498" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34905252" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Assessing the risk of thromboembolism in cancer patients receiving immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036293" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877523" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34521106" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235597" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Erythropoietin or darbepoetin for patients with cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
